Perennial rice beats its other cultivated rice counterparts by being more stress tolerant, reducing production costs by over 50%. BGI Genomics research aims to bring more disease-resistant variants to farmers across 18 countries, to alleviate world hunger.

“When we consider the potential savings, enhanced yield as well as environmental benefits, perennial rice can be truly revolutionary for farmers,” said Dr. Liu Huan, BGI Bioverse.

About BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.